INTENSITY THERAPEUTICS INC (INTS) Fundamental Analysis & Valuation

NASDAQ:INTS • US45828J2024

Current stock price

6.03 USD
-0.08 (-1.31%)
At close:
6.04 USD
+0.01 (+0.17%)
After Hours:

This INTS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. INTS Profitability Analysis

1.1 Basic Checks

  • INTS had negative earnings in the past year.
  • In the past year INTS has reported a negative cash flow from operations.
  • In the past 5 years INTS always reported negative net income.
  • In the past 5 years INTS always reported negative operating cash flow.
INTS Yearly Net Income VS EBIT VS OCF VS FCFINTS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -122.44%, INTS is doing worse than 80.73% of the companies in the same industry.
  • INTS's Return On Equity of -162.50% is on the low side compared to the rest of the industry. INTS is outperformed by 65.70% of its industry peers.
Industry RankSector Rank
ROA -122.44%
ROE -162.5%
ROIC N/A
ROA(3y)-280.06%
ROA(5y)-210.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
INTS Yearly ROA, ROE, ROICINTS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 500 -500

1.3 Margins

  • INTS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INTS Yearly Profit, Operating, Gross MarginsINTS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. INTS Health Analysis

2.1 Basic Checks

  • INTS has more shares outstanding than it did 1 year ago.
  • There is no outstanding debt for INTS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
INTS Yearly Shares OutstandingINTS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 200K 400K 600K
INTS Yearly Total Debt VS Total AssetsINTS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

  • INTS has an Altman-Z score of -10.53. This is a bad value and indicates that INTS is not financially healthy and even has some risk of bankruptcy.
  • INTS has a worse Altman-Z score (-10.53) than 72.83% of its industry peers.
  • There is no outstanding debt for INTS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.53
ROIC/WACCN/A
WACCN/A
INTS Yearly LT Debt VS Equity VS FCFINTS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 5M -5M 10M -10M -15M

2.3 Liquidity

  • A Current Ratio of 3.60 indicates that INTS has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 3.60, INTS is in line with its industry, outperforming 43.16% of the companies in the same industry.
  • INTS has a Quick Ratio of 3.60. This indicates that INTS is financially healthy and has no problem in meeting its short term obligations.
  • INTS has a Quick ratio (3.60) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.6
Quick Ratio 3.6
INTS Yearly Current Assets VS Current LiabilitesINTS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. INTS Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 41.12% over the past year.
EPS 1Y (TTM)41.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 15.27% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y70.79%
EPS Next 2Y34.63%
EPS Next 3Y21.5%
EPS Next 5Y15.27%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
INTS Yearly Revenue VS EstimatesINTS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M
INTS Yearly EPS VS EstimatesINTS Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 0 10 -10 -20 -30

More info and screens

Find the best growth stocksShow best growing peers

1

4. INTS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for INTS. In the last year negative earnings were reported.
  • Also next year INTS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INTS Price Earnings VS Forward Price EarningsINTS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INTS Per share dataINTS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

  • INTS's earnings are expected to grow with 21.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.63%
EPS Next 3Y21.5%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. INTS Dividend Analysis

5.1 Amount

  • INTS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

INTS Fundamentals: All Metrics, Ratios and Statistics

INTENSITY THERAPEUTICS INC

NASDAQ:INTS (3/27/2026, 8:26:24 PM)

After market: 6.04 +0.01 (+0.17%)

6.03

-0.08 (-1.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-12
Earnings (Next)N/A
Inst Owners5.93%
Inst Owner Change32.34%
Ins Owners7.24%
Ins Owner Change1.11%
Market Cap15.26M
Revenue(TTM)N/A
Net Income(TTM)-11.74M
Analysts80
Price Target64.6 (971.31%)
Short Float %N/A
Short Ratio0.07
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)34.12%
Min EPS beat(2)32.77%
Max EPS beat(2)35.47%
EPS beat(4)3
Avg EPS beat(4)15.34%
Min EPS beat(4)-10.61%
Max EPS beat(4)35.47%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-13.14%
PT rev (3m)2071.4%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2531.58%
EPS NY rev (1m)-2400%
EPS NY rev (3m)-2400%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.11
P/tB 2.11
EV/EBITDA N/A
EPS(TTM)-15.75
EYN/A
EPS(NY)-5.48
Fwd EYN/A
FCF(TTM)-3.75
FCFYN/A
OCF(TTM)-3.75
OCFYN/A
SpS0
BVpS2.85
TBVpS2.85
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -122.44%
ROE -162.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-280.06%
ROA(5y)-210.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.6
Quick Ratio 3.6
Altman-Z -10.53
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76%
EPS Next Y70.79%
EPS Next 2Y34.63%
EPS Next 3Y21.5%
EPS Next 5Y15.27%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y28.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-20.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-20.37%
OCF growth 3YN/A
OCF growth 5YN/A

INTENSITY THERAPEUTICS INC / INTS Fundamental Analysis FAQ

What is the fundamental rating for INTS stock?

ChartMill assigns a fundamental rating of 2 / 10 to INTS.


Can you provide the valuation status for INTENSITY THERAPEUTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to INTENSITY THERAPEUTICS INC (INTS). This can be considered as Overvalued.


How profitable is INTENSITY THERAPEUTICS INC (INTS) stock?

INTENSITY THERAPEUTICS INC (INTS) has a profitability rating of 0 / 10.


Can you provide the financial health for INTS stock?

The financial health rating of INTENSITY THERAPEUTICS INC (INTS) is 6 / 10.